The COVID-19 pandemic highlights the risks associated with the collection and processing of human biospecimens with an unknown status for the coronavirus SARS-CoV-2, whether for diagnostic, therapeutic, or research purposes. …
Colorectal cancer (CRC) is a challenging disease, with a high mortality rate and limited effective treatment options, particularly for late-stage disease. Historically, human CRC cell lines have been used in vitro …
Registrations open for the two virtual biobanking conferences: ISBER 2020 Virtual Symposium: ISBER and UHN Biospecimen Services, Canada have partnered to provide a two-day virtual symposium for the international biobanking …
East Tennessee State University and the James H. Quillen Veterans Affairs Medical Center at Mountain Home are seeking patients who have recovered from COVID-19 to donate a sample of their …
The global pandemic of COVID-19, caused by the highly infectious and transmissible coronavirus, SARS-CoV-2, has become a leading cause of death in older adults. While adults can develop life-threatening complications …
Here is your monthly curated pick of biobanking news, jobs, and events from across the globe. We hope you will find this enriching and useful. Please do let us know …
NIH’s ‘National Heart, Lung, and Blood Institute’ launched the REDS-IV-P program. This program is conducting the RESPONSE study (REDS-IV-P Epidemiology, Surveillance, and Preparedness of the Novel SARS-CoV-2 Epidemic) which aims …
The University of Western Australia (UWA) adopts OpenSpecimen as its Biobanking LIMS. Implemented as part of The Western Australian Health Translation Network (WAHTN) the WA Biobank will use OpenSpecimen to create, for the first time, a …
Outbreaks of infectious diseases are occurring with increasing frequency and unpredictability. The rapid development and deployment of diagnostics that can accurately and quickly identify pathogens as part of epidemic preparedness …
For precision medicine to realize its potential, research must become ultraefficient. We have the computing power today to quickly discover new disease biomarkers and insights, but we still need enormous …